Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE-IMI 2: Imipenem/Relebactam/Cilastatin vs Piperacillin/Tazobactam in HABP/VAPB
NCT02493764Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2015
- Primary completion
- Apr 2019
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of relebactam in hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP), sponsored by Merck & Co.. Started Nov 2015; status: completed.
02
Drugs
relebactam
03
Conditions
hospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT02493764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02493764.